---
title: "Alterity Therapeutics FY26 net loss widens to $23.4 million; R&D expenses rise 22% to A$17.63 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297332009.md"
description: "Alterity Therapeutics reported a widened FY26 net loss of $23.4 million, up from $12.1 million previously. R&D expenses rose 22% to A$17.63 million, while general and administrative costs surged 92% to A$10.53 million. Operating cash outflow increased to $22.5 million, though cash equivalents grew to A$37.32 million. The company also executed a 50-to-1 capital consolidation effective May 29, 2026."
datetime: "2026-08-28T13:16:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297332009.md)
  - [en](https://longbridge.com/en/news/297332009.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297332009.md)
generator: "portal-rs"
---

# Alterity Therapeutics FY26 net loss widens to $23.4 million; R&D expenses rise 22% to A$17.63 million

-   Alterity Therapeutics posted a net loss of U.S.$23.4 million, widening from U.S.$12.1 million in the prior year. \* Operating cash outflow widened to U.S.$22.5 million from U.S.$11.5 million; cash and cash equivalents rose to A$37.32 million. \* Research and development expenses climbed 22% to A$17.63 million; general and administrative costs jumped 92% to A$10.53 million. \* Interest income rose to A$1.72 million from A$446,291; other income included A$3.61 million tied to the R&D Tax Incentive. \* An issued capital consolidation of 50-to-1 took effect on May 29, 2026; unexercised options totaled 66,200,000 at June 30. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-029135), on August 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ATHE.US](https://longbridge.com/en/quote/ATHE.US.md)
- [ATH.AU](https://longbridge.com/en/quote/ATH.AU.md)

## Related News & Research

- [Alterity Therapeutics Confirms Phase 3 Trial Pathway for ATH434](https://longbridge.com/en/news/303666013.md)
- [Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update | ATHE Stock News](https://longbridge.com/en/news/303735570.md)
- [Alterity Therapeutics issues 8,400,000 shares tied to exercised options at A$ 0.5 each](https://longbridge.com/en/news/298298137.md)
- [Alterity Therapeutics CEO Participates in Fireside Chat at Craig-Hallum Biotech Catalyst Conference](https://longbridge.com/en/news/302271084.md)
- [Alterity Therapeutics issues shares from exercise of listed options at A$0.5 each](https://longbridge.com/en/news/297504784.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**